Veradigm Files Fiscal 2022 Form 10-K and Restated Financial Statements
Veradigm (OTCMKTS: MDRX) has filed its Annual Report on Form 10-K for fiscal year 2022, including restated financial statements for periods in 2022, 2021, and 2020. The filing marks a important step toward regaining compliance with financial reporting obligations.
Interim CEO Tom Langan emphasized the company's focus on addressing material weaknesses, remedying internal control deficiencies, becoming current in financial reporting, and working toward relisting their common stock. Interim CFO Lee Westerfield confirmed that the revenue adjustments from continuing operations align with estimates previously disclosed in the Form 12b-25 filed on March 4, 2025.
Veradigm (OTCMKTS: MDRX) ha presentato il suo Rapporto Annuale sul Modulo 10-K per l'anno fiscale 2022, inclusi i bilanci rettificati per i periodi del 2022, 2021 e 2020. Questa presentazione segna un passo importante verso il recupero della conformità con gli obblighi di reporting finanziario.
Il CEO ad interim Tom Langan ha sottolineato l'impegno dell'azienda nel affrontare le debolezze materiali, rimediare alle carenze nei controlli interni, diventare attuale nel reporting finanziario e lavorare per la riammissione delle azioni ordinarie. Il CFO ad interim Lee Westerfield ha confermato che le rettifiche sui ricavi delle operazioni continuative sono in linea con le stime precedentemente divulgate nel Modulo 12b-25 presentato il 4 marzo 2025.
Veradigm (OTCMKTS: MDRX) ha presentado su Informe Anual en el Formulario 10-K para el año fiscal 2022, incluidos los estados financieros rectificados para los períodos de 2022, 2021 y 2020. Esta presentación marca un paso importante hacia la recuperación de la conformidad con las obligaciones de informes financieros.
El CEO interino Tom Langan enfatizó el enfoque de la empresa en abordar las debilidades materiales, remediar las deficiencias en el control interno, estar al día en los informes financieros y trabajar hacia la re-lista de sus acciones ordinarias. El CFO interino Lee Westerfield confirmó que los ajustes de ingresos de las operaciones continuas se alinean con las estimaciones previamente divulgadas en el Formulario 12b-25 presentado el 4 de marzo de 2025.
Veradigm (OTCMKTS: MDRX)는 2022 회계연도에 대한 10-K 양식의 연간 보고서를 제출했으며, 2022년, 2021년 및 2020년의 재무제표를 수정하여 포함했습니다. 이 제출은 재무 보고 의무를 준수하기 위한 중요한 단계로 여겨집니다.
임시 CEO인 톰 랭건은 회사가 중요한 약점을 해결하고 내부 통제의 결함을 수정하며, 재무 보고를 최신 상태로 유지하고, 보통주를 재상장하기 위해 노력하고 있음을 강조했습니다. 임시 CFO인 리 웨스터필드는 계속 운영에서의 수익 조정이 2025년 3월 4일에 제출된 12b-25 양식에서 이전에 공개된 추정치와 일치한다고 확인했습니다.
Veradigm (OTCMKTS: MDRX) a déposé son Rapport Annuel sur le Formulaire 10-K pour l'exercice fiscal 2022, y compris des états financiers rectifiés pour les périodes de 2022, 2021 et 2020. Ce dépôt marque une étape importante vers le rétablissement de la conformité avec les obligations de reporting financier.
Le PDG par intérim Tom Langan a souligné l'engagement de l'entreprise à traiter les faiblesses matérielles, à remédier aux déficiences de contrôle interne, à se mettre à jour dans le reporting financier et à travailler à la nouvelle cotation de leurs actions ordinaires. Le directeur financier par intérim Lee Westerfield a confirmé que les ajustements de revenus des opérations continues sont conformes aux estimations précédemment divulguées dans le Formulaire 12b-25 déposé le 4 mars 2025.
Veradigm (OTCMKTS: MDRX) hat seinen Jahresbericht auf Formular 10-K für das Geschäftsjahr 2022 eingereicht, einschließlich berichtiger Finanzberichte für die Jahre 2022, 2021 und 2020. Diese Einreichung stellt einen wichtigen Schritt zur Wiederherstellung der Konformität mit den finanziellen Berichtspflichten dar.
Der vorläufige CEO Tom Langan betonte den Fokus des Unternehmens auf die Behebung wesentlicher Schwächen, die Beseitigung interner Kontrollmängel, die Aktualisierung der Finanzberichterstattung und die Arbeit an der Wiederzulassung ihrer Stammaktien. Der interimistische CFO Lee Westerfield bestätigte, dass die Umsatzanpassungen aus fortlaufenden Betrieben mit den zuvor im Formular 12b-25 am 4. März 2025 offengelegten Schätzungen übereinstimmen.
- Filed comprehensive 2022 Form 10-K with restated financials
- Revenue adjustments align with previously disclosed estimates
- Progress toward regaining financial reporting compliance
- Material weaknesses in internal controls remain unresolved
- Company delisted from major exchange to OTC markets
- Required restatement of three years of financial statements
“This filing represents an important step toward regaining compliance with our financial reporting obligations,” said Tom Langan, Interim Chief Executive Officer of Veradigm. “We remain focused on remediating our material weaknesses and other internal control deficiencies, becoming current in our financial reporting, executing against our growth strategy to deliver end-to-end solutions for our clients, and relisting our common stock. I would like to recognize our Veradigm employees for the dedication and work to earn our customers’ business every day.”
“We are pleased to have filed the 2022 Form 10-K as part of a comprehensive undertaking that involved a detailed and thorough examination of our financial statements, as well as our accounting policies and processes,” said Lee Westerfield, Interim Chief Financial Officer of Veradigm.
The adjustments to the Company’s revenue from continuing operations in the 2022 Form 10-K are consistent with the amounts that were estimated in the Form 12b-25 filed by the Company on March 4, 2025.
For further information regarding the circumstances that led to the financial statement restatements and the Company’s remediation efforts, please see the sections entitled “Explanatory Note” and Item 9A, “Controls and Procedures”, in the 2022 Form 10-K.
About Veradigm®
Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube.
© 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
| Table 1 | ||||||
Veradigm Inc. |
||||||
Condensed Consolidated Balance Sheets |
||||||
(In millions) |
||||||
(Unaudited) |
||||||
|
|
|
|
(As Restated) |
|
(As Restated) |
|
|
December 31, |
|
December 31, |
|
December 31, |
|
2022 |
|
2021 |
|
2020 |
|
| ASSETS | ||||||
| Current assets: | ||||||
| Cash and cash equivalents |
|
|
|
|||
| Restricted cash | 1.3 |
1.3 |
5.5 |
|||
| Accounts receivable, net | 119.1 |
119.7 |
122.5 |
|||
| Contract assets | 56.6 |
65.2 |
63.2 |
|||
| Income tax receivable | 0.0 |
0.0 |
25.4 |
|||
| Prepaid expenses and other current assets | 56.0 |
51.8 |
47.7 |
|||
| Current assets attributable to discontinued operations | 0.0 |
277.6 |
349.2 |
|||
| Total current assets |
|
|
|
|||
| Fixed assets, net | 9.5 |
17.7 |
29.2 |
|||
| Software development costs, net | 75.1 |
81.2 |
81.6 |
|||
| Intangible assets, net | 89.3 |
149.7 |
166.0 |
|||
| Goodwill | 532.6 |
498.4 |
498.6 |
|||
| Deferred taxes, net | 37.2 |
0.0 |
0.0 |
|||
| Contract assets - long-term | 0.0 |
0.0 |
0.0 |
|||
| Right-of-use assets - operating leases | 12.0 |
18.3 |
27.1 |
|||
| Other assets | 69.4 |
79.7 |
65.2 |
|||
| Long-term assets attributable to discontinued operations | 0.0 |
816.8 |
909.5 |
|||
| Total assets |
|
|
|
|||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||
| Current liabilities: | ||||||
| Accounts payable |
|
|
|
|||
| Accrued expenses | 66.8 |
62.9 |
68.3 |
|||
| Accrued compensation and benefits | 35.9 |
30.3 |
41.8 |
|||
| Deferred revenue | 90.1 |
87.9 |
115.3 |
|||
| Current operating lease liabilities | 6.6 |
6.1 |
6.6 |
|||
| Current liabilities attributable to discontinued operations | 0.0 |
299.0 |
697.3 |
|||
| Total current liabilities | 230.3 |
488.4 |
942.1 |
|||
| Long-term debt | 200.4 |
350.1 |
167.6 |
|||
| Deferred revenue | 0.0 |
0.2 |
0.1 |
|||
| Deferred taxes, net | 0.0 |
18.7 |
18.2 |
|||
| Long-term operating lease liabilities | 12.4 |
16.8 |
22.9 |
|||
| Other liabilities | 44.1 |
33.8 |
32.5 |
|||
| Long-term liabilities attributable to discontinued operations | 0.0 |
42.7 |
66.7 |
|||
| Total liabilities |
|
|
|
|||
| Total stockholders’ equity |
|
|
|
|||
| Total liabilities and stockholders’ equity |
|
|
|
|||
| Table 2 | |||||||||
| Veradigm Inc. | |||||||||
| Condensed Consolidated Statements of Operations | |||||||||
| (In millions, except per share amounts) | |||||||||
| (Unaudited) | |||||||||
|
|
|
|
|
|||||
Twelve Months Ended December 31, |
|||||||||
|
|
(As Restated) |
|
(As Restated) |
|||||
2022 |
|
|
2021 |
|
|
2020 |
|
||
| Revenue: | |||||||||
| Provider |
|
|
|
|
|
|
|||
| Payer & Life Science | 122.1 |
|
99.0 |
|
93.1 |
|
|||
| Total Revenue | 588.0 |
|
577.4 |
|
556.1 |
|
|||
| Cost of revenue: | |||||||||
| Provider | 232.8 |
|
244.2 |
|
247.8 |
|
|||
| Payer & Life Science | 46.8 |
|
50.8 |
|
44.1 |
|
|||
| Total cost of revenue | 279.6 |
|
295.0 |
|
291.9 |
|
|||
| Gross profit | 308.4 |
|
282.4 |
|
264.2 |
|
|||
| Selling, general and administrative expenses | 169.2 |
|
111.8 |
|
155.7 |
|
|||
| Research and development | 97.9 |
|
84.1 |
|
78.6 |
|
|||
| Asset impairment charges | 7.5 |
|
0.5 |
|
10.2 |
|
|||
| Amortization of intangible and acquisition-related assets | 60.9 |
|
9.3 |
|
11.9 |
|
|||
| Income (loss) from operations | (27.1 |
) |
76.7 |
|
7.8 |
|
|||
| Interest income (expense), net (a) | (1.7 |
) |
(12.7 |
) |
(33.8 |
) |
|||
| Other income (expense) | (35.0 |
) |
93.7 |
|
13.3 |
|
|||
| Income (loss) before income taxes | (63.8 |
) |
157.7 |
|
(12.7 |
) |
|||
| Income tax (provision) benefit | 43.8 |
|
(29.9 |
) |
(15.0 |
) |
|||
| Income (loss) from continuing operations, net of tax | (20.0 |
) |
127.8 |
|
(27.7 |
) |
|||
| Income (loss) from discontinued operations | (7.1 |
) |
15.8 |
|
(70.9 |
) |
|||
| Gain (loss) on sale of discontinued operations | (10.3 |
) |
0.6 |
|
1,156.8 |
|
|||
| Income tax (provision) benefit from discontinued operations | (49.0 |
) |
(4.5 |
) |
(362.2 |
) |
|||
| Income (loss) from discontinued operations, net of tax | (66.4 |
) |
11.9 |
|
723.7 |
|
|||
| Net Income (loss) |
( |
) |
|
|
|
|
|||
| Diluted earnings per Common Share: | |||||||||
| Income (loss) from continuing operations, net of tax |
( |
) |
|
|
( |
) |
|||
| Plus: Interest expense, net of tax1 |
|
|
|
|
|
|
|||
| Income (loss) from continuing operations2 | (20.0 |
) |
127.8 |
|
(27.7 |
) |
|||
| Income (loss) from discontinued operations, net of tax | (66.4 |
) |
11.9 |
|
723.7 |
|
|||
| Net Income (loss)2 |
( |
) |
|
|
|
|
|||
| Income (loss) from continuing operations per share - basic |
( |
) |
|
|
( |
) |
|||
| Income (loss) from discontinued operations per share - basic |
( |
) |
|
|
|
|
|||
| Income (loss) per share - basic |
( |
) |
|
|
|
|
|||
| Income (loss) from continuing operations per share - diluted2 |
( |
) |
|
|
( |
) |
|||
| Income (loss) from discontinued operations per share - diluted |
( |
) |
|
|
|
|
|||
| Income (loss) per share - diluted2 |
( |
) |
|
|
|
|
|||
| Weighted average common shares outstanding: | |||||||||
| Basic | 112.1 |
|
130.1 |
|
159.3 |
|
|||
| Diluted | 112.1 |
|
138.7 |
|
159.3 |
|
|||
Twelve Months Ended December 31, |
|||||||||
|
|
Restated |
|
Restated |
|||||
2022 |
|
|
2021 |
|
|
2020 |
|
||
| (a) Interest income (expense), net | |||||||||
| Interest expense | (4.1 |
) |
(5.4 |
) |
(18.3 |
) |
|||
| Interest income | 4.7 |
|
0.2 |
|
0.5 |
|
|||
| Non-cash charges to interest expense | (2.3 |
) |
(7.5 |
) |
(16.0 |
) |
|||
| Interest income (expense), net |
( |
) |
( |
) |
( |
) |
|||
| 1Associated with |
|||||||||
| 2Net of tax after the effect of assumed conversions of convertible notes | |||||||||
| Table 3 | |||||||||
| Veradigm Inc. | |||||||||
| Condensed Non-GAAP Financial Information | |||||||||
| (In millions, except per share amounts and percentages) | |||||||||
| (Unaudited) | |||||||||
| Twelve Months Ended December 31, | |||||||||
| (As Restated) |
(As Restated) |
||||||||
2022 |
2021 |
2020 |
|||||||
| Revenue, GAAP |
|
|
|
|
|
|
|||
| Gross profit, GAAP |
|
|
|
|
|
|
|||
| Depreciation and amortization | 37.0 |
|
37.5 |
|
33.6 |
|
|||
| Acquisition-related amortization | 6.8 |
|
7.1 |
|
9.9 |
|
|||
| Stock-based compensation expense | 1.3 |
|
1.1 |
|
1.7 |
|
|||
| Total non-GAAP gross profit |
|
|
|
|
|
|
|||
| Non-GAAP Gross margin 1 | 60.1 |
% |
56.8 |
% |
55.6 |
% |
|||
| Net Income |
( |
) |
|
|
|
|
|||
| Less: | |||||||||
| Loss (income) from discontinued operations |
|
|
( |
) |
|
|
|||
| Loss (gain) on sale of business, net from discontinued operations |
|
|
( |
) |
( |
) |
|||
| Income tax provision (benefit) from discontinued operations |
|
|
|
|
|
|
|||
| Income (loss) from continuing operations, net of tax, GAAP |
( |
) |
|
|
( |
) |
|||
| Plus: | |||||||||
| Interest (income) expense, net | 1.7 |
|
12.7 |
|
33.8 |
|
|||
| Other (income) expense | 35.0 |
|
(93.7 |
) |
(13.3 |
) |
|||
| Depreciation and amortization | 113.5 |
|
65.3 |
|
71.2 |
|
|||
| Income tax (benefit) provision | (43.8 |
) |
29.9 |
|
15.0 |
|
|||
| Stock-based compensation expense | 29.6 |
|
13.6 |
|
13.5 |
|
|||
| Asset impairment charges | 7.5 |
|
0.5 |
|
10.2 |
|
|||
| Transaction and other | 17.9 |
|
12.6 |
|
19.6 |
|
|||
| Adjusted EBITDA |
|
|
|
|
|
|
|||
| Adjusted EBITDA margin 2 | 24.0 |
% |
29.2 |
% |
22.0 |
% |
|||
| Net Income |
( |
) |
|
|
|
|
|||
| Plus: Interest expense, net of tax4 | 0.0 |
|
0.0 |
|
0.0 |
|
|||
| Net Income (loss)3 |
( |
) |
|
|
|
|
|||
| Loss (income) from discontinued operations | 7.1 |
|
(15.8 |
) |
70.9 |
|
|||
| (Gain) on sale of business, net from discontinued operations | 10.3 |
|
(0.6 |
) |
(1,156.8 |
) |
|||
| Income tax provision (benefit) from discontinued operations | 49.0 |
|
4.5 |
|
362.2 |
|
|||
| Income (loss) from continuing operations3 |
( |
) |
|
|
( |
) |
|||
| Less: Interest expense, net of tax4 | 0.0 |
|
0.0 |
|
0.0 |
|
|||
| Income (loss) from continuing operations, net of tax |
( |
) |
|
|
( |
) |
|||
| Acquisition-related amortization | 67.7 |
|
16.3 |
|
21.7 |
|
|||
| Stock-based compensation expense | 29.6 |
|
13.6 |
|
13.5 |
|
|||
| Transaction and other | 17.9 |
|
12.6 |
|
19.6 |
|
|||
| Other non-operating (income) expense | 16.0 |
|
0.3 |
|
16.5 |
|
|||
| Asset impairment charges | 7.5 |
|
0.0 |
|
10.2 |
|
|||
| Tax rate alignment | (61.8 |
) |
(18.2 |
) |
(1.6 |
) |
|||
| Non-GAAP net income |
|
|
|
|
|
|
|||
| GAAP effective tax rate | 69 |
% |
19 |
% |
-120 |
% |
|||
| Non-GAAP effective tax rate | 24 |
% |
24 |
% |
24 |
% |
|||
| Weighted shares outstanding - basic | 112.1 |
|
130.1 |
|
159.3 |
|
|||
| Weighted shares outstanding - diluted | 112.1 |
|
138.7 |
|
159.3 |
|
|||
| The net effect of convertible notes and note hedges | 5.0 |
|
(2.8 |
) |
2.7 |
|
|||
| Non-GAAP Weighted shares outstanding - diluted | 117.1 |
|
135.9 |
|
162.0 |
|
|||
| Income (loss) from continuing operations per share - diluted3 |
( |
) |
|
|
( |
) |
|||
| Income (loss) from discontinued operations per share - diluted |
( |
) |
|
|
|
|
|||
| Income (loss) per share - diluted3 |
( |
) |
|
|
|
|
|||
| Non-GAAP Income (loss) per share - diluted |
|
|
|
|
|
|
|||
| 1 Non-GAAP Gross margin is calculated by dividing Non-GAAP Gross profit by revenue. | |||||||||
| 2 Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by revenue. | |||||||||
| 3 Net of tax after the effect of assumed conversions of convertible notes | |||||||||
| 4 Associated with |
|||||||||
| Table 4 | |||||||||||||||||||||||||
| Veradigm Inc. | |||||||||||||||||||||||||
| Supplemental Condensed Non-GAAP Financial Information | |||||||||||||||||||||||||
| (In millions, except per share amounts) | |||||||||||||||||||||||||
| (unaudited) | |||||||||||||||||||||||||
2020 |
|
2021 |
|
|
|
|
|
2022 |
|
|
|
|
|
||||||||||||
(As Restated) |
(As Restated) |
(As Restated) |
(As Restated) |
(As Restated) |
|||||||||||||||||||||
| Total | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |||||||||||||||
| Provider | |||||||||||||||||||||||||
| Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Gross profit, Non-GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Gross margin, Non-GAAP 1 | 55.0 |
% |
55.9 |
% |
56.0 |
% |
54.3 |
% |
60.0 |
% |
56.6 |
% |
57.0 |
% |
55.2 |
% |
57.4 |
% |
59.8 |
% |
57.4 |
% |
|||
| Payer & Life Science | |||||||||||||||||||||||||
| Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Gross profit, Non-GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Gross margin, Non-GAAP 1 | 58.9 |
% |
55.1 |
% |
57.4 |
% |
57.6 |
% |
60.4 |
% |
57.8 |
% |
63.0 |
% |
71.8 |
% |
70.7 |
% |
74.3 |
% |
70.5 |
% |
|||
| Total Veradigm | |||||||||||||||||||||||||
| Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Gross profit, Non-GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Gross margin, Non-GAAP 1 | 55.6 |
% |
55.8 |
% |
56.2 |
% |
54.8 |
% |
60.1 |
% |
56.8 |
% |
58.0 |
% |
59.1 |
% |
60.2 |
% |
62.9 |
% |
60.1 |
% |
|||
| Adjusted EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Adjusted EBITDA margin2 | 22.0 |
% |
24.0 |
% |
27.6 |
% |
25.5 |
% |
38.5 |
% |
29.2 |
% |
20.2 |
% |
25.3 |
% |
23.2 |
% |
27.1 |
% |
24.0 |
% |
|||
| Net Income, Non-GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Non-GAAP Weighted shares outstanding - diluted | 162.0 |
|
146.5 |
|
142.0 |
|
128.6 |
|
125.3 |
|
135.9 |
|
125.1 |
|
119.6 |
|
113.3 |
|
111.1 |
|
117.1 |
|
|||
| Non-GAAP Income (loss) per share - diluted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| 1 Non-GAAP Gross margin is calculated by dividing Non-GAAP Gross profit by revenue. | |||||||||||||||||||||||||
| 2 Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by revenue. | |||||||||||||||||||||||||
| Table 5 | |||||||||||||||||||||||||
| Veradigm Inc. | |||||||||||||||||||||||||
| Supplemental Non-GAAP Financial Information Reconciliation - Financial Trend Details | |||||||||||||||||||||||||
| (In millions) | |||||||||||||||||||||||||
| (unaudited) | |||||||||||||||||||||||||
2020 |
|
|
2021 |
|
|
|
|
|
|
2022 |
|
|
|
|
|
||||||||||
(As Restated) |
|
(As Restated) |
|
(As Restated) |
(As Restated) |
(As Restated) |
|
||||||||||||||||||
| Total | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |||||||||||||||
| Provider | |||||||||||||||||||||||||
| Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Gross profit, GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Depreciation and amortization | 29.8 |
|
7.7 |
|
7.9 |
|
7.8 |
|
7.1 |
|
30.5 |
|
7.2 |
|
6.9 |
|
6.8 |
|
7.5 |
|
28.4 |
|
|||
| Acquisition-related amortization | 8.1 |
|
1.3 |
|
1.3 |
|
1.3 |
|
1.4 |
|
5.3 |
|
1.1 |
|
1.1 |
|
1.1 |
|
1.4 |
|
4.7 |
|
|||
| Stock-based compensation expense | 1.5 |
|
0.1 |
|
0.1 |
|
0.1 |
|
0.6 |
|
0.9 |
|
0.4 |
|
0.3 |
|
0.4 |
|
0.1 |
|
1.2 |
|
|||
| Gross profit, Non-GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Payer & Life Science | |||||||||||||||||||||||||
| Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Gross profit, GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Depreciation and amortization | 3.8 |
|
1.7 |
|
1.7 |
|
1.8 |
|
1.8 |
|
7.0 |
|
2.2 |
|
2.2 |
|
2.2 |
|
2.0 |
|
8.6 |
|
|||
| Acquisition-related amortization | 1.8 |
|
0.5 |
|
0.5 |
|
0.5 |
|
0.3 |
|
1.8 |
|
0.5 |
|
0.6 |
|
0.6 |
|
0.4 |
|
2.1 |
|
|||
| Stock-based compensation expense | 0.2 |
|
0.1 |
|
0.1 |
|
0.1 |
|
(0.1 |
) |
0.2 |
|
0.0 |
|
0.0 |
|
0.0 |
|
0.1 |
|
0.1 |
|
|||
| Gross profit, Non-GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Table 6 | |||||||||||||||||||||||||
| Veradigm Inc. | |||||||||||||||||||||||||
| Supplemental Non-GAAP Financial Information Reconciliation - Financial Trend Details | |||||||||||||||||||||||||
| (In millions, except per share amounts) | |||||||||||||||||||||||||
| (unaudited) | |||||||||||||||||||||||||
2020 |
|
|
2021 |
|
|
|
|
|
|
2022 |
|
|
|
|
|
||||||||||
(As Restated) |
|
(As Restated) |
|
(As Restated) |
(As Restated) |
(As Restated) |
|
|
|||||||||||||||||
| Total | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |||||||||||||||
| Total Veradigm | |||||||||||||||||||||||||
| Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Gross profit, GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Depreciation and amortization | 33.6 |
|
9.4 |
|
9.6 |
|
9.6 |
|
8.9 |
|
37.5 |
|
9.4 |
|
9.1 |
|
9.0 |
|
9.5 |
|
37.0 |
|
|||
| Acquisition-related amortization | 9.9 |
|
1.8 |
|
1.8 |
|
1.8 |
|
1.7 |
|
7.1 |
|
1.6 |
|
1.7 |
|
1.7 |
|
1.8 |
|
6.8 |
|
|||
| Stock-based compensation expense | 1.7 |
|
0.2 |
|
0.2 |
|
0.2 |
|
0.5 |
|
1.1 |
|
0.4 |
|
0.3 |
|
0.4 |
|
0.2 |
|
1.3 |
|
|||
| Gross profit, Non-GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Net Income (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
( |
) |
( |
) |
( |
) |
|||
| Interest expense, net of tax2 | 0.0 |
|
0.0 |
|
0.0 |
|
0.0 |
|
0.0 |
|
0.0 |
|
0.5 |
|
0.0 |
|
0.0 |
|
0.0 |
|
0.0 |
|
|||
| Net Income (loss)1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
( |
) |
( |
) |
( |
) |
|||
| Loss (income) from discontinued operations | 70.9 |
|
(19.0 |
) |
(3.2 |
) |
6.8 |
|
(0.4 |
) |
(15.8 |
) |
4.3 |
|
3.0 |
|
0.5 |
|
(0.7 |
) |
7.1 |
|
|||
| Loss (gain) on sale of business, net from discontinued operations | (1,156.8 |
) |
(0.6 |
) |
0.0 |
|
0.0 |
|
0.0 |
|
(0.6 |
) |
0.0 |
|
10.3 |
|
0.0 |
|
0.0 |
|
10.3 |
|
|||
| Income tax provision (benefit) from discontinued operations | 362.2 |
|
5.1 |
|
0.2 |
|
(2.0 |
) |
1.2 |
|
4.5 |
|
(9.8 |
) |
61.4 |
|
(3.0 |
) |
0.4 |
|
49.0 |
|
|||
| Income (loss) from continuing operations1 |
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
( |
) |
( |
) |
( |
) |
|||
| Interest expense, net of tax2 | 0.0 |
|
0.0 |
|
0.0 |
|
0.0 |
|
0.0 |
|
0.0 |
|
(0.5 |
) |
0.0 |
|
0.0 |
|
0.0 |
|
0.0 |
|
|||
| Net Income (loss) from continuing operations, GAAP |
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
( |
) |
( |
) |
( |
) |
|||
| Interest (income) expense, net | 33.8 |
|
2.8 |
|
2.9 |
|
3.6 |
|
3.4 |
|
12.7 |
|
2.1 |
|
1.8 |
|
(0.4 |
) |
(1.8 |
) |
1.7 |
|
|||
| Other (income) expense | (13.3 |
) |
(1.2 |
) |
(18.3 |
) |
(14.0 |
) |
(60.2 |
) |
(93.7 |
) |
(0.1 |
) |
30.0 |
|
3.9 |
|
1.2 |
|
35.0 |
|
|||
| Depreciation and amortization | 71.2 |
|
16.7 |
|
16.7 |
|
16.5 |
|
15.4 |
|
65.3 |
|
15.7 |
|
28.4 |
|
34.6 |
|
34.8 |
|
113.5 |
|
|||
| Income tax (benefit) provision | 15.0 |
|
2.9 |
|
3.6 |
|
5.9 |
|
17.5 |
|
29.9 |
|
(23.7 |
) |
(28.0 |
) |
(10.0 |
) |
17.9 |
|
(43.8 |
) |
|||
| Stock-based compensation expense | 13.5 |
|
3.6 |
|
3.5 |
|
3.2 |
|
3.3 |
|
13.6 |
|
6.9 |
|
10.5 |
|
5.7 |
|
6.5 |
|
29.6 |
|
|||
| Asset impairment charges | 10.2 |
|
0.0 |
|
0.2 |
|
0.4 |
|
(0.1 |
) |
0.5 |
|
2.0 |
|
0.4 |
|
1.2 |
|
3.9 |
|
7.5 |
|
|||
| Transaction and other | 19.6 |
|
1.8 |
|
1.9 |
|
2.1 |
|
6.8 |
|
12.6 |
|
6.7 |
|
2.7 |
|
1.8 |
|
6.7 |
|
17.9 |
|
|||
| Adjusted EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| Income (loss) from continuing operations, net of tax, as reported |
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
( |
) |
( |
) |
( |
) |
|||
| Acquisition-related amortization | 21.7 |
|
4.1 |
|
4.1 |
|
4.1 |
|
4.0 |
|
16.3 |
|
3.8 |
|
17.0 |
|
23.5 |
|
23.4 |
|
67.7 |
|
|||
| Stock-based compensation expense | 13.5 |
|
3.6 |
|
3.5 |
|
3.2 |
|
3.3 |
|
13.6 |
|
6.9 |
|
10.5 |
|
5.7 |
|
6.5 |
|
29.6 |
|
|||
| Transaction and other | 19.6 |
|
1.8 |
|
1.9 |
|
2.1 |
|
6.8 |
|
12.6 |
|
6.7 |
|
2.7 |
|
1.8 |
|
6.7 |
|
17.9 |
|
|||
| Other non-operating (income) expense | 16.5 |
|
1.3 |
|
(3.6 |
) |
1.3 |
|
1.3 |
|
0.3 |
|
0.0 |
|
14.4 |
|
1.4 |
|
0.2 |
|
16.0 |
|
|||
| (Gain) loss on business transactions | 0.0 |
|
0.0 |
|
0.0 |
|
(0.0 |
) |
0.0 |
|
(0.0 |
) |
0.0 |
|
0.0 |
|
0.0 |
|
(0.0 |
) |
(0.0 |
) |
|||
| Asset impairment charges | 10.2 |
|
0.0 |
|
0.0 |
|
0.0 |
|
0.0 |
|
0.0 |
|
2.0 |
|
0.4 |
|
1.2 |
|
3.9 |
|
7.5 |
|
|||
| Tax rate alignment | (1.6 |
) |
(1.8 |
) |
(5.5 |
) |
(2.6 |
) |
(8.3 |
) |
(18.2 |
) |
(27.0 |
) |
(30.1 |
) |
(15.0 |
) |
10.2 |
|
(61.8 |
) |
|||
| Non-GAAP net income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| GAAP effective tax rate | -120 |
% |
34 |
% |
11 |
% |
24 |
% |
19 |
% |
19 |
% |
425 |
% |
77 |
% |
77 |
% |
-201 |
% |
69 |
% |
|||
| Non-GAAP effective tax rate | 24 |
% |
24 |
% |
24 |
% |
24 |
% |
24 |
% |
24 |
% |
24 |
% |
24 |
% |
24 |
% |
24 |
% |
24 |
% |
|||
| Weighted shares outstanding - basic | 159.3 |
|
140.2 |
|
136.6 |
|
123.9 |
|
120.1 |
|
130.1 |
|
115.9 |
|
114.3 |
|
110.2 |
|
108.1 |
|
112.1 |
|
|||
| Weighted shares outstanding - diluted | 162.0 |
|
149.1 |
|
145.3 |
|
131.4 |
|
127.8 |
|
138.7 |
|
138.7 |
|
118.7 |
|
113.3 |
|
111.1 |
|
116.8 |
|
|||
| Less the net effect of convertible notes and note hedges | 0.0 |
|
(2.6 |
) |
(3.3 |
) |
(2.8 |
) |
(2.5 |
) |
(2.8 |
) |
(13.6 |
) |
0.9 |
|
0.0 |
|
0.0 |
|
0.3 |
|
|||
| Non-GAAP Weighted shares outstanding - diluted | 162.0 |
|
146.5 |
|
142.0 |
|
128.6 |
|
125.3 |
|
135.9 |
|
125.1 |
|
119.6 |
|
113.3 |
|
111.1 |
|
117.1 |
|
|||
| Income (loss) from continuing operations per share - diluted2 |
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
( |
) |
( |
) |
( |
) |
|||
| Income (loss) from discontinued operations per share - diluted |
|
|
|
|
|
|
( |
) |
( |
) |
|
|
|
|
( |
) |
|
|
|
|
( |
) |
|||
| Income (loss) per share - diluted2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
( |
) |
( |
) |
( |
) |
|||
| Non-GAAP Net Income (loss) per share - diluted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
| 1Net of tax after the effect of assumed conversions of convertible notes | |||||||||||||||||||||||||
| 2Associated with |
|||||||||||||||||||||||||
Explanation of Non-GAAP Financial Measures
Veradigm reports its financial results in accordance with
- Non-GAAP gross profit consists of GAAP gross profit, as reported, and excludes acquisition-related amortization; stock-based compensation expense; and depreciation and amortization. Reconciliations to GAAP gross profit are found in Tables 3, 5, and 6 within this press release.
- Non-GAAP gross margin is a non-GAAP measure that is calculated by dividing non-GAAP gross profit by revenue.
- Adjusted EBITDA is a non-GAAP financial measure and consists of GAAP net income/(loss) from continuing operations and adjusts for: interest (income)/expense, net; other (income)/expense; depreciation and amortization; income tax (benefit)/provision; stock-based compensation expense; asset impairment charges; and transaction and other revenue and expenses. Reconciliations to GAAP net income/(loss) are found in Tables 3 and 6 within this press release.
- Adjusted EBITDA margin is a non-GAAP measure that is calculated by dividing Adjusted EBITDA by revenue. See the reconciliations in Tables 3 and 6 within this press release with respect to Adjusted EBITDA.
- Non-GAAP effective income tax rate is based on non-GAAP pre-tax earnings and consists of the statutory federal income tax rate, Veradigm effective state income tax rate and adjustments for permanent differences.
- Non-GAAP net income (loss) consists of GAAP net income/(loss), as reported, less discontinued operations and adds back acquisition-related amortization; stock-based compensation expense; asset impairment charges; transaction and other revenue and expenses; and non-cash charges to interest expense and other. Non-GAAP net income also includes a GAAP to non-GAAP tax rate alignment adjustment. Reconciliations to GAAP net income (loss) are found in Tables 3 and 6 within this press release.
-
Non-GAAP diluted weighted shares outstanding consists of diluted weighted shares outstanding, as reported, less the dilutive impact of the Company’s
0.875% convertible notes (the “convertible notes”) due to the intent to settle the principal in cash and shares to be delivered at settlement by the convertible note hedge. - Non-GAAP diluted income (loss) per share consists of non-GAAP net income, as defined above, divided by non-GAAP diluted weighted shares outstanding, as defined above, during the applicable period.
Management believes that non-GAAP gross profit, gross margin, Adjusted EBITDA, Adjusted EBITDA margin, effective income tax rate, net income (loss), diluted weighted shares outstanding and diluted income (loss) per share provide useful supplemental information to management and investors regarding the underlying performance of Veradigm business operations. Acquisition accounting adjustments and transaction and other revenue and expenses recorded in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments provided and discussed herein.
Management also uses this information internally for forecasting and budgeting, as it believes that these measures are indicative of core operating results. In addition, management may use non-GAAP diluted income (loss) per share and Adjusted EBITDA to measure achievement under Veradigm’s stock and cash incentive compensation plans. Note, however, that non-GAAP diluted income (loss) per share and Adjusted EBITDA are performance measures only, and they do not provide any measure of cash flow or liquidity.
Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Veradigm’s results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the definitions and reconciliations of non-GAAP financial measures with GAAP financial measures contained within this press release.
Acquisition-Related Amortization. Acquisition-related amortization expense is a non-cash expense arising primarily from the acquisition of intangible assets in connection with acquisitions or investments. Veradigm excludes acquisition-related amortization expense from non-GAAP gross profit, non-GAAP gross margin, non-GAAP net income, Adjusted EBITDA and Adjusted EBITDA margin because it believes (i) the amount of such expenses in any specific period may not directly correlate with the underlying performance of Veradigm’s business operations and (ii) such expenses can vary significantly between periods because of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation, and the related amortization expense will recur in future periods.
Stock-Based Compensation Expense. Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards. Veradigm excludes stock-based compensation expense from non-GAAP gross profit, non-GAAP gross margin, non-GAAP net income (loss) and Adjusted EBITDA because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Veradigm business operations and (ii) such expenses can vary significantly between periods as a result of the timing and valuation of grants of new stock-based awards, including grants in connection with acquisitions. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods, and such expense will recur in future periods.
Asset impairment charges. Asset impairment charges, which are excluded from Adjusted EBITDA, Adjusted EBITDA margin and Non-GAAP net income (loss), reflect non-cash charges related to the abandonment of certain leased spaces and write-offs based on management’s assessment of the likelihood of near-term recovery of certain investments’ value.
Depreciation and Amortization. Depreciation and amortization, which are excluded from non-GAAP gross profit, non-GAAP gross margin, Adjusted EBITDA and Adjusted EBITDA margin, are non-cash expenses arising from allocating the cost of fixed assets, intangibles and capitalized software over time.
Transaction and Other. Transaction and other revenue and expenses relate to certain favorable and unfavorable legal settlements, severance, investigations, internal reviews, restatement-related accounting and legal advisory services and other charges incurred in connection with activities that are considered not reflective of our core business. Veradigm excludes transaction and other revenue and expenses from non-GAAP net income (loss), Adjusted EBITDA and Adjusted EBITDA margin because it believes (i) the amount of such revenue or expenses in any specific period may not directly correlate to the underlying performance of Veradigm business operations and (ii) such revenue or expenses can vary significantly between periods.
Non-Cash Charges to Interest Expense and Other. Non-cash charges to interest expense include the amortization of the discount and debt issuance costs associated with the convertible notes. Other includes certain other income and expense and impairments on long-term investments and gains and losses on business transactions and certain asset disposals.
Tax Rate Alignment. Tax rate alignment aligns the applicable period’s effective tax rate to the expected annual non-GAAP effective tax rate.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250318984157/en/
Investors:
Jenny Gelinas
312-506-1237
jenny.gelinas@veradigm.com
Media:
Amanda Cohen
412-919-2417
amanda.cohen@veradigm.com
Source: Veradigm
FAQ
What financial periods were restated in Veradigm's (MDRX) 2022 Form 10-K filing?
Why did Veradigm (MDRX) have to restate its financial statements?
What are Veradigm's (MDRX) next steps after filing the 2022 Form 10-K?
Is Veradigm (MDRX) currently trading on a major exchange?
